Manchester Score for Prognosis in Small Cell Lung Cancer
The Manchester Score provides a simple clinical stratification tool to estimate prognosis in small cell lung cancer.
Serum LDH > upper limit of normal
No0Yes+1
Serum Na < 132 mmol/L
No0Yes+1
Serum alk phos > 1.5x the upper limit of normal
No0Yes+1
Serum bicarbonate < 24
No0Yes+1
Extensive stage disease
No0Yes+1
Karnofsky Performance Status
100 - Normal. No complaints. No evidence of disease090 - Able to carry on normal activity. minor signs/symptoms of disease080 - Normal activity w/ effort. Some signs/symptoms of disease070 - Care for self. Unable to carry on normal activity or to do active work060 - Requires occasional assistance, but is able to care for most his/her personal needs050 - Requires considerable assistance and frequent medical care+140 - Disable. Requires special care and assistance+130 - Severely disabled. Hospital admission is indicated although death is not imminent+120 - Very sick. Hospital admission necessary. Active supportive treatment necessary+110 - Moribund. Fatal processes progressing rapidly+1
Indications d'utilisation
Used in newly diagnosed SCLC to stratify prognosis using simple baseline factors (PS, serum sodium, LDH, and liver metastases). Guides risk communication, helps frame expected survival, and supports treatment‑intensity decisions in settings where rapid prognostication is needed. Its prognostic value has been externally validated in independent cohorts 1 [Level II evidence].
Informations et précautions
Stratifies SCLC prognosis using simple clinical variables but offers only moderate predictive ability; external cohorts confirmed utility over more complex models 1 [Level III evidence].
- Easy to apply; validated in real‑world settings.
- Does not incorporate modern biomarkers or radiomics.
- Underperforms for individualized prediction, as most multivariable SCLC scores show limited accuracy 2 [Level II evidence].
- Use cautiously; supplement with staging, PS, and LDH.